Citations

Showing 10 of 108104 citations.

Editor's evaluation: Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin
Ekker, Stephen C.

Mayo Clinic

No container title available | February 23, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.65421.sa0 Get It

Response by Egbe to Letter Regarding Article, “Right Heart Dysfunction in Adults With Coarctation of Aorta: Prevalence and Prognostic Implications”
Egbe, Alexander C. , Egbe, Alexander C

Mayo Clinic

Circulation: Cardiovascular Imaging | February 23, 2022 | Volume: 15 | Issue: 3 | Pages: No page available

10.1161/circimaging.122.014007 | PMID 35193362 Get It

Low antispike antibody levels correlate with poor outcomes in COVID‐19 breakthrough hospitalizations
Sanghavi, Devang , Bhakta, Shivang , Wadei, Hani M. , Bosch, Wendelyn , Cowart, Jennifer B. , Carter, Rickey E. , Shah, Sadia , Pollock, Benjamin D. , Neville, Matthew R., Oman, Sven P. , Speicher, Leigh L. , Siegel, Jason , Scindia, Ameya D., Matson, Mark W., Sanghavi, Devang K., Shah, Sadia Z. , Speicher, Leigh, Kunze, Katie L. , Carter, Rickey E , Wadei, Hani M , Pollock, Benjamin D , Libertin, Claudia R. , Johnson, Patrick W. , Franco, Pablo Moreno

Mayo Clinic

Journal of Internal Medicine | February 23, 2022 | Volume: 292 | Issue: 1 | Pages: 127-135

10.1111/joim.13471 | PMID 35194861 Get It

AbstractBackgroundWhile COVID‐19 immunization programs attempted to reach targeted rates, cases rose significantly since the emergence of the delta variant. This retrospective cohort study describes the correlation between antispike antibodies and outcomes of hospitalized, breakthrough cases during the delta variant surge.MethodsAll patients with positive SARS‐CoV‐2 polymerase chain reaction hospitalized at Mayo Clinic Florida from 19 June 2021 to 11 November 2021 were considered for analysis. Cases were analyzed by vaccination status. Breakthrough cases were then analyzed by low and high antibody titers against SARS‐CoV‐2 spike protein, with a cut‐off value of ≥132 U/ml. Outcomes included hospital length of stay (LOS), need for intensive care unit (ICU), mechanical ventilation, and mortality. We used 1:1 nearest neighbor propensity score matching without replacement to assess for confounders.ResultsAmong 627 hospitalized patients with COVID‐19, vaccine breakthrough cases were older with more comorbidities compared to unvaccinated. After propensity score matching, the unvaccinated patients had higher mortality (27 [28.4%] vs. 12 [12.6%], p = 0.002) and LOS (7 [1.0–57.0] vs. 5 [1.0–31.0] days, p = 0.011). In breakthrough cases, low‐titer patients were more likely to be solid organ transplant recipients (16 [34.0%] vs. 9 [12.3%], p = 0.006), with higher need for ICU care (24 [51.1%] vs. 22 [11.0%], p = 0.034), longer hospital LOS (median 6 vs. 5 days, p = 0.013), and higher mortality (10 [21.3%] vs. 5 [6.8%], p = 0.025) than high‐titer patients.ConclusionsHospitalized breakthrough cases were more likely to have underlying risk factors than unvaccinated patients. Low‐spike antibody titers may serve as an indicator for poor prognosis in breakthrough cases admitted to the hospital.
Inflammatory Bowel Disease: An Indication to Screen for Thrombophilia?
Moukalled, Nour , Taher, Alì , Taher, Ali T , Hashash, Jana G.

Mayo Clinic

Diseases | February 23, 2022 | Volume: 10 | Issue: 1 | Pages: 14

10.3390/diseases10010014 | PMID 35323181 Get It

Inflammatory bowel diseases (IBD) are systemic conditions characterized by multiple intestinal and extra-intestinal manifestations related to the associated chronic inflammatory state. Among their diverse extra-intestinal complications, venous thromboembolism (VTE) remains one of the most under recognized causes of morbidity and mortality in these patients, highlighting the need for a better understanding of the underlying mechanism of hypercoagulability, in addition to the role of acquired and inherited risk factors that further increase the risk of thrombosis with its impact on patients’ outcomes. We hereby present a review of the data regarding thrombosis in the setting of IBD, elucidating the possible role for screening in this high-risk category of patients and specifically in areas where inherited thrombophilia is expected to be highly prevalent, reporting two patients with IBD, one who developed a cerebrovascular event and another one who had recurrent VTE events; nevertheless, both of them had inherited thrombophilic mutations. The identification of specific genetic abnormalities in those patients reintroduces the controversy related to the need to screen a specific category of patients with IBD for hereditary thrombophilia, especially in regions characterized by a higher prevalence of such thrombophilic alterations.
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
Totzeck, Matthias , Michel, Lars , Lin, Yi , Herrmann, Joerg , Lin, Yi , Rassaf, Tienush

Mayo Clinic

European Heart Journal | February 23, 2022 | Volume: 43 | Issue: 20 | Pages: 1928-1940

10.1093/eurheartj/ehac106 | PMID 35257157 Get It

Abstract Chimeric antigen receptor (CAR)-T cell therapy is the next revolutionary advance in cancer therapy. By using ex vivo engineered T cells to specifically target antigens, a targeted immune reaction is induced. Chimeric antigen receptor-T cell therapy is approved for patients suffering from advanced and refractory B cell and plasma cell malignancies and is undergoing testing for various other haematologic and solid malignancies. In the process of triggering an anticancer immune reaction, a systemic inflammatory response can emerge as cytokine release syndrome (CRS). The severity of CRS is highly variable across patients, ranging from mild flu-like symptoms to fulminant hyperinflammatory states with excessive immune activation, associated multiorgan failure and high mortality risk. Cytokine release syndrome is also an important factor for adverse cardiovascular (CV) events. Sinus tachycardia and hypotension are the most common reflections, similar to what is seen with other systemic inflammatory response syndromes. Corrected QT interval prolongation and tachyarrhythmias, including ventricular arrhythmias and atrial fibrillation, also show a close link with CRS. Events of myocardial ischaemia and venous thromboembolism can be provoked during CAR-T cell therapy. Although not as closely related to CRS, changes in cardiac function can be observed to the point of heart failure and cardiogenic shock. This may also be encountered in patients with severe valvular heart disease in the setting of CRS. This review will discuss the pertinent CV risks of the growing field of CAR-T cell therapy for today’s cardiologists, including incidence, characteristics, and treatment options, and will conclude with an integrated management algorithm.
Comparison of outcomes between pessary use and surgery for symptomatic pelvic organ prolapse: A prospective self-controlled study
Linder, Brian J. , Gebhart, John B. , Weaver, Amy L. , Fick, Felecia R., Harvey-Springer, Randina R., Trabuco, Emanuel C. , Klingele, Christopher J., Occhino, John A. , Linder, Brian J

Mayo Clinic

Investigative and Clinical Urology | February 23, 2022 | Volume: 63 | Issue: 2 | Pages: 214

10.4111/icu.20210395 | PMID 35244996 Get It

Recurrent Mitral Regurgitation After MitraClip: Defining Success and Predicting Outcomes
Hassan, Abdalla, Eleid, Mackram F. , Hassan, Abdalla, Eleid, Mackram F

Mayo Clinic

Circulation: Cardiovascular Interventions | February 23, 2022 | Volume: 15 | Issue: 3 | Pages: No page available

10.1161/circinterventions.122.011837 | PMID 35193381 Get It

Single Arterial Access for Ecpella and Jugular Venous Cannulation Provides Full Mobility on a Status 1 Heart Transplant Recipient
Bitargil, Macit , Haddad, Osama , Sareyyüpoğlu, Başar , Sareyyupoglu, Basar , Pham, Si M.

Mayo Clinic

ESC Heart Failure | February 23, 2022 | Volume: 9 | Issue: 3 | Pages: 2003-2006

10.1002/ehf2.13862 | PMID 35194962 Get It

Abstract Concomitant treatment with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella may improve outcomes in patients with cardiogenic shock compared with VA-ECMO alone. Here, we explain a new method to introduce Impella and ECMO through the same arterial access site and jugular venous cannulation to accomplish a mobile patient concept.
Publicly Available Pricing Information for Orthopaedic Upper Extremity Procedures in the United States Lacks Transparency and Consistency Between Major Hospitals
Moore, M. Lane , Pollock, Jordan R. , Haglin, Jack M. , Scott, Kelly, Doan, Matthew K. , Scott, Kelly L, Bingham, Joshua S. , Moore, M Lane , Pollock, Jordan Riley , Patel, Karan A.

Mayo Clinic

Arthroscopy, Sports Medicine, and Rehabilitation | February 23, 2022 | Volume: 4 | Issue: 3 | Pages: No page available

10.1016/j.asmr.2022.01.005 | PMID 35747661 Get It

Purpose The purpose of this study was to assess the price variation of various Medicare severity diagnosis‐related group codes for orthopaedic upper extremity procedures for the top 20 orthopaedic hospitals using chargemaster price listings from each hospital. Methods The top 20 orthopaedic hospitals in the United States were determined by querying the U.S. News and World Report ’s 2020 orthopaedic hospital ranking. This report ranks orthopaedic hospitals according to 4 major domains: outcomes, structure, process/expert opinion, and patient experience. Chargemaster data for the top 20 orthopaedic hospitals was compiled from their websites. Five DRG codes that represented orthopaedic upper extremity procedures were selected, and the pricing information for each was extracted from hospital chargemasters. The median income and cost‐of‐living index were also compiled for the county that each hospital is located in so that pricing data could be compared to economic measures through regression analysis. Results Of the top 20 orthopaedic hospitals, 18 had publicly available pricing information in DRG format on their websites. The DRG code with the highest pricing variability was Hand Injury Procedures (DRG 906; range, $12,832‐$253,633). The procedure with the least pricing variability was Hand or Wrist Procedures (DRG 514; range, $24,533‐$128,403). Additionally, only the cost of living index was a statistically significant predictor of procedure pricing with a weak correlation. Conclusion Hospital chargemaster listings are lacking in 2 major areas: true price transparency and standardization/consistency between hospitals. Chargemaster data are often difficult to find, confusing to patients, and inaccurate. Additionally, the price range for a single DRG code can also vary substantially depending on the hospital. It is possible that hospitals located in areas with high costs of living and median incomes would charge higher prices, but these factors were not found to support this hypothesis.
The Usefulness of Prognostic Tools in Breast Cancer Patients with Brain Metastases
Radecka, Barbara , Ali, Shan , Mandat, Tomasz , Duchnowska, Renata , Ali, Shan , Duchnowska, Renata , Kufel-Grabowska, Joanna , Niwińska, Anna

Mayo Clinic

Cancers | February 22, 2022 | Volume: 14 | Issue: 5 | Pages: 1099

10.3390/cancers14051099 | PMID 35267407 Get It

Background: Determining the proper therapy is challenging in breast cancer (BC) patients with brain metastases (BM) due to the variability of an individual’s prognosis and the variety of treatment options available. Several prognostic tools for BC patients with BM have been proposed. Our review summarizes the current knowledge on this topic. Methods: We searched PubMed for prognostic tools concerning BC patients with BM, published from January 1997 (since the Radiation Therapy Oncology Group developed) to December 2021. Our criteria were limited to adults with newly diagnosed BM regardless of the presence or absence of any leptomeningeal metastases. Results: 31 prognostic tools were selected: 13 analyzed mixed cohorts with some BC cases and 18 exclusively analyzed BC prognostic tools. The majority of prognostic tools in BC patients with BM included: the performance status, the age at BM diagnosis, the number of BM (rarely the volume), the primary tumor phenotype/genotype and the extracranial metastasis status as a result of systemic therapy. The prognostic tools differed in their specific cut-off values. Conclusion: Prognostic tools have variable precision in determining the survival of BC patients with BM. Advances in local and systemic treatment significantly affect survival, therefore, it is necessary to update the survival indices used depending on the type and period of treatment.